newsfilter
← Latest News
Business Wire·

City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial

Half of the enrolled patients had stable disease for at least two months, two showed partial response and two experienced complete response Nature Medicine paper highlights delivery of CAR T cell therapy directly to